Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics Inc (ATXS) is a biopharmaceutical innovator developing monoclonal antibody therapies for rare immunological conditions like hereditary angioedema and atopic dermatitis. This page aggregates all official company announcements and verified news updates for stakeholders tracking its preclinical pipeline and scientific advancements.
Investors and researchers will find timely updates on clinical developments, regulatory milestones, and strategic partnerships. Our curated feed includes progress reports on key candidates like plasma kallikrein inhibitors and OX40 antagonists, along with analyses of their potential impact on underserved patient populations.
Content spans trial design announcements, patent filings, executive commentary, and peer-reviewed research collaborations. All materials are vetted for accuracy and presented in chronological order to help users track the company's evolving position in the rare disease therapeutics market.
Bookmark this page for streamlined access to ATXS's latest scientific disclosures and corporate developments. Check regularly for updates on antibody engineering breakthroughs and preclinical validation studies shaping the future of immune disorder treatments.
Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company specializing in allergic and immunological diseases, has announced its participation in the 2024 Wedbush PacGrow Healthcare Conference in New York, NY. The company's CEO, Jill C. Milne, Ph.D., will be part of a panel discussion titled 'HAE Ya! The Changing Face of the HAE Therapeutic Landscape' on Wednesday, August 14 at 2:30pm ET.
This panel will focus on hereditary angioedema (HAE), a rare genetic disorder that causes severe swelling in various parts of the body. Astria's participation in this conference highlights its commitment to advancing therapies for HAE and other immunological conditions, potentially impacting its stock performance and investor interest in the biopharmaceutical sector.
Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company focused on allergic and immunological diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The options, totaling 29,150 shares of common stock, were awarded on August 1, 2024, with an exercise price of $11.19 per share, matching the closing price on the grant date.
These options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement awards to new employees.
Astria Therapeutics (Nasdaq: ATXS) announced the grant of stock options for 123,500 shares of its common stock on July 1, 2024, under its 2022 Inducement Stock Incentive Plan.
This grant, aimed at three new employees, aligns with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for their employment.
Each option has an exercise price of $9.25, equal to the closing price on the grant date, and will vest over four years.
25% of the shares will vest after the first year of employment, with the remainder vesting monthly over the next three years, contingent on continued employment.
Astria Therapeutics announced on June 3, 2024, that it has granted stock options to purchase 40,000 shares of common stock under its 2022 Inducement Stock Incentive Plan. These options were provided as an inducement to a new employee, with the exercise price set at $9.16, matching the closing price of the stock on the grant date. The vesting schedule spans four years: 25% on the first anniversary of the employee's start date and the remaining shares vesting monthly over the next 36 months. The grants comply with Nasdaq Listing Rule 5635(c)(4).
Astria Therapeutics (NASDAQ: ATXS), a biopharmaceutical company specializing in therapies for allergic and immunological conditions, announced that CEO Jill C. Milne, Ph.D., will participate in a fireside chat at the Jefferies Healthcare Conference. The event is scheduled for June 6th at 10:00am ET in New York, NY. A webcast of the presentation will be available live and as an archived replay for 30 days on the company's investor relations website.
Astria Therapeutics (NASDAQ: ATXS) will present final Phase 1a data for STAR-0215 at the Eastern Allergy Conference in Palm Beach, Florida, on June 1, 2024. The focus will be on updated results for hereditary angioedema treatment. Jessica Best, VP of Medical Affairs, will present the poster at 9:45am EST.
Astria Therapeutics (NASDAQ: ATXS) will present two posters at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain, on June 1, 2024.
Dr. Marcus Maurer will present the ALPHA-SOLAR trial of STAR-0215 for treating hereditary angioedema (HAE), detailing its rationale and design.
Dr. Nikos Biris will present on the characterization of STAR-0310, a novel OX40 antagonistic monoclonal antibody.
Both sessions will take place on June 1 at 12:00pm CEST.
Astria Therapeutics, Inc. (NASDAQ:ATXS) reported financial results for Q1 2024, highlighting the positive proof-of-concept results of STAR-0215 for HAE treatment. The company plans to start Phase 3 trials in Q1 2025 and expand label with Q6M administration. Moreover, Astria is developing STAR-0310 for atopic dermatitis and aims to submit an IND application by 2024. The company also shared corporate updates and financial results.
Astria Therapeutics, a biopharmaceutical company, will be presenting information on STAR-0310 at the Society for Investigative Dermatology Annual Meeting. The presentation will focus on the preclinical profile of a novel OX40 antagonistic monoclonal antibody. Dr. Chunxia Lily Zhao will present the poster at the event in May 2024.
Astria Therapeutics, Inc. (Nasdaq:ATXS) granted stock options to purchase 173,500 shares of common stock under the 2022 Inducement Stock Incentive Plan to new employees. The options have an exercise price of $9.50, vesting over four years, with 25% vesting after one year and the rest monthly over 36 months, contingent on continued employment.
FAQ
What is the current stock price of Astria Therapeutics (ATXS)?
What is the market cap of Astria Therapeutics (ATXS)?
